A double-blind, randomized, multiple-dose, parallel-group study to characterize the occurrence of diarrhea following two different dosing regimens of neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor

被引：0

作者：

Richat Abbas

Bruce A. Hug

Cathie Leister

Daryl Sonnichsen

机构：

[1] Pfizer Inc,

来源：

Cancer Chemotherapy and Pharmacology | 2012年 / 70卷

关键词：

ErbB2 inhibitor; Diarrhea; Dose regimen; Healthy subjects; Pharmacokinetics;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：191 / 199

页数：8

共 301 条

[41]

Coleman R(undefined)undefined undefined undefined undefined-undefined

[42]

Wardley A(undefined)undefined undefined undefined undefined-undefined

[43]

Harbeck N(undefined)undefined undefined undefined undefined-undefined

[44]

Lopez RI(undefined)undefined undefined undefined undefined-undefined

[45]

Mallmann P(undefined)undefined undefined undefined undefined-undefined

[46]

Gelmon K(undefined)undefined undefined undefined undefined-undefined

[47]

Wilcken N(undefined)undefined undefined undefined undefined-undefined

[48]

Wist E(undefined)undefined undefined undefined undefined-undefined

[49]

Sanchez RP(undefined)undefined undefined undefined undefined-undefined

[50]

Piccart-Gebhart MJ(undefined)undefined undefined undefined undefined-undefined